Esomeprazole Magnesium Capsule, Delayed Release
Product Images NDC 70518-4581

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Esomeprazole Magnesium (NDC 70518-4581). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Esomeprazolemagnesiumfigure1 (Esomeprazolemagnesiumfigure1)

Esomeprazolemagnesiumfigure1 (Esomeprazolemagnesiumfigure1)
Chemical structure of esomeprazole magnesium, showing the molecular arrangement including magnesium ions and water molecules, corresponding to the compound used as the active ingredient in Esomeprazole Magnesium delayed-release capsules.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Esomeprazole Magnesium 40 mg delayed-release capsules label displaying quantity of 30 capsules. The label includes storage instructions, mentions 'Rx Only', and states the product is repackaged by RemedyRepack Inc. of Indiana, PA. The original manufacturer is Camber Pharma, Inc., Piscataway, NJ. The NDC is 70518-4581-00.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph comparing the percentage maintained over 6 months for Esomeprazole Magnesium Delayed-Release Capsules at 40 mg, 20 mg, 10 mg doses, and placebo. The x-axis represents time in months, and the y-axis shows percent maintained. The 40 mg dose shows the highest maintenance followed by 20 mg, 10 mg, and placebo showing the lowest values.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line graph illustrating the percent maintained over six months for various doses of Esomeprazole Magnesium Delayed-Release Capsules and placebo. The x-axis represents months, and the y-axis represents percent maintained. Four lines depict 40 mg, 20 mg, 10 mg doses, and placebo, showing higher percent maintained for 40 mg compared to lower doses and placebo over time.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph showing the percent of patients symptom-free over a 28-day diary period. The graph compares Esomeprazole Magnesium Delayed-Release Capsules 40 mg, 20 mg, and placebo groups, illustrating symptom-free percentages on the vertical axis and diary days on the horizontal axis.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A line graph showing the percentage of patients symptom-free over a 28-day diary period for three groups: Esomeprazole Magnesium Delayed-Release Capsules 40 mg, 20 mg, and placebo. The graph indicates higher symptom-free percentages in both Esomeprazole groups compared to placebo, with data points tracked daily.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.